Replies to post #33468 on Ayala Pharmaceuticals Inc (ADXS)

[mpreorder]

Only for you FBG - please re-read it yourself. Here is the paragraph, again, that's under item 2:

ADXS-HER2 is an Lm –based antigen delivery product designed to target HER2 expressing solid tumors including human and canine osteosarcoma. The dose finding phase of the trial is complete. The Company has evaluated the data and decided not to proceed to the expansion phase of the trial. In addition, based on the Company’s priorities, the ADXS-HER2 development program, which includes Pediatric Osteosarcoma, will be discontinued but remains open to investigator-initiated research or licensing proposals.

Now be nice and say you're sorry.....